Full Press Release Details
Eidos Therapeutics Receives Positive Opinion For Orphan Designation From The European Medicines Agency For AG10, A Potent Oral Stabilizer For The Treatment Of Transthyretin Amyloidosis.
BBIO
Eidos Therapeutics Receives Positive Opinion For Orphan Designation From The European Medicines Agency For AG10, A Potent Oral Stabilizer For The Treatment Of Transthyretin Amyloidosis
Key Takeaway: Eidos Therapeutics Receives Positive Opinion For Orphan Designation From The European Medicines Agency For AG10, A Potent Oral Stabilizer For The Treatment Of Transthyretin Amyloidosis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis